Back to Awarded Treatment Trials
Awarded Trial: 01T-078
Grant ID
01T-078
Illness
Schizophrenia
Primary Drug/Intervention
Atomoxetine
Primary Dosage
40mg bid
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Conley
Sample Size
30
Duration of Study Period for Each Subject
8 weeks
Outcome Measurements
Cognitive Battery, BPRS, SANS, CGI
Results
Twenty-eight patients were randomized and completed the study. There was no significant difference between atomoxetine and placebo on measures of cognition or symptom severity.
Publication
N/A
Link
N/A
PI Name
Robert Conley
Degree
MD
Center
Maryland Psychiatric Research Center
Institution
University of Maryland
Address
PO Box 21247
City or Town
Baltimore
State or Province
MD
Zip or Postal Code
21228
Country
USA
Email Address
rconley@mprc.umaryland.edu